Evolus, Inc. Common Stock · NASDAQ:EOLS
Evolus, Inc. Common Stock — Investor Presentation (January 2019)
21 slides from Evolus, Inc. Common Stock's investor presentation, Jan 4, 2019
Slide 1: Slide 1
Slide 2: Special Note Regarding Forward-Looking Statements
Special Note Regarding Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy;
Slide 3: Launching a New Chapter in Aesthetics
Launching a New Chapter in Aesthetics New Product Candidate Jeuveau™ (prabotulinumtoxinA-xvfs) . Expected to be the first known 900 kilodalton (“kDa”) molecule in the U.S. since Botox launched EU / Canada Phase III head-to-head data versus market leader met primary endpoint PDUFA action date of Feb.
Slide 4: Medical Aesthetics: One of the Fastest Growing Markets in Healthcare
Medical Aestheties: ONE OF THE FASTEST GROWING MARKETS IN HEALTHCARE! The neurotoxin market represents the largest segment and remains highly underpenetrated! Global Aesthetic Neurotoxin Sales ($mm)? $2,207 $2,393 $1,876 $2,035 $1,191 $931 $1,005 $1,094 2017E 2018E 2019E 2020E BU.S. © EX-U.S. Evolus
Slide 5: Highly Experienced Management Team
Highly Experienced Management Team & é David Moatazedi Lauren Silvernail Rui Avelar, MD Michael Jafar President and CEO CFO and EVP, Chief Medical Officer Chief Marketing Officer Corporate Development and Head of R&D Amy Fox Jeff Plumer Kurt Knab Alex Sabad Vice President, Vice President, Legal Vice
Slide 6: Rapidly Advancing to Commercialization
Rapidly Advancing to Commerecialization (1) David Moatazedi joined Evolus as President and CEO © Manufacturing facility pre-cleared by FDA for commercial manufacturing (3) DWP-450 granted approval by Health Canada (4) FDA resubmission accepted, new action date Feb. 2, 2019 (5) Completed build out of
Slide 7: Jeuveau: The First Known 900kDa Alternative to Botox
Jeuveau™ Jeuveau™ is the First Known 900kDa Alternative to Botox Current competitors to Botox have different molecular weights U.S. Aesthetics Market Share! Molecule Size Aesthetics Only? 900 kDa? Undisclosed 20.5% X 150 kDa’ 9.5% X 4, 2018..2. Zhang, Leta 3.Xeomin FDA Label
Slide 8: >2,100 Patients Studied Across Multiple Clinical Trials
>2,100 Patients Studied Across Multiple Clinical Trials U.S. Phase III: EU / Canada Phase III: = P Jeuveau™ vs. Placebo Jeuveau™ vs. Botox Jouve Saiisihy Sicice * Two identical Phase III safety and * EU/ Canada Phase Ill safety and * U.S. Phase Il Long-Term Safety efficacy studies (EV-001 & EV-002)
Slide 9: Primary Endpoint
Primary Endpoint Composite Score (investigator and subject agree) 2 2 Point GLS Improvement at Maximum Frown on Day 30 so eM 70.4% 60% 0% 40% 30% 20% 10% 1.2% 1.3% o% J Jeuveau™ Placebo Jeuveau™ Placebo n=246 n=84 n=246 n=78 Secondary Endpoint 22 Point Composite GLS Improvement at Maximum Frown (inv
Slide 10: US Phase III: Jeuveau vs. Placebo Exploratory Endpoints: EV-001 and EV-002
T™ US. Phase I: Jeuveau VS. Placebo Exploratory Endpoints: EV-001 and EV-002 RESPONDER RATES THROUGH FIVE MONTHS 21 Point Improvement GLS at Maximum Frown (%) Investigator Assessment Subject Assessment 100 64 88 100 100 50 946 100 oo os 90 * 90 80 m2 7 70 648 70 60 60 8 oe M8 a 40 40 30 20 20 10 oO
Slide 11: EU / Canada Phase III: Jeuveau vs. Botox
EU / Canada Phase III: Jeuveau™ vs. Botox Meets Primary Endpoint When Compared Head to Head with Botox Primary Endpoint Primary Endpoint + Responder Rates at Day 30 + Non-inferiority at Day 30 * GLS=0orlat Maximum Frown by * Responder Defined as GLS = 0 orlat Investigator Assessment Maximum Frown by
Slide 12: Jeuveau Safety Studies
Jeuveau™ Safety Studies > 2,100 Subjects Studied with No Drug Related Serious Adverse Events U.S. Safety Profile: Adverse Events Placebo Jeuveau™ Placebo Jeuveau™ All 32.1% 38.2% 26.9% 28.5% Related 13.1% 15.4% 77% 9.8% EU Safety Profile: Adverse Events Placebo BOTOX Jeuveau™ All 32.7% 419% 37.6% Re
Slide 13: Differentiated
Differentiated r Marketing Frictionless Alternative
Slide 14: Strategically focusing on today and tomorrow
Strategically focusing on today and tomorrow Targeting the Largest Population* Significant Opportunity Open to Trial Projected population by generation’ ¢ BOTULINUM TOXIN USE 7 3 MILLION In millions AMONG PEOPLE AGED 19 MILLENIALS 90 TO 34 INCREASED BY 87% BETWEEN 2011 AND 20162 VS 72 MILLION BABY B
Slide 15: Jeuveau Frictionless Alternative
Jeuveau™ Frictionless Alternative Let's get started IS | 4.2% o &@ 3 % Y % $4 Jeuveau™ Botox Placebo n=235 n=244 n=48 15
Slide 16: Financial Overview: Strong Cash Position
Financial Overview: Strong Cash Position IN USD (UNAUDITED) Operating Expenses: Non-GAAP! $17.1M Net Loss: Non-GAAP" $17.9M Earnings per Share: Non-GAAP! ($0.77) Cash $105.2M Weighted-Average Shares Outstanding 23,417,417 Q4 2018 Non-GAAP Operating Expense Guidance $12M - $15M (as provided 11/5/18)
Slide 17: Key 2019 Catalysts
Key 2019 Catalysts Expected Launch in Three Major Markets (1) PDUFA date of February 2, 2019 (2) Expect U.S. commercial launch in Spring 2019 Anticipated Publications: U.S Trials in Q1’19, EU / Canada head-to-head trials in Q2’19 EU CHMP opinion expected in Q1’19; if positive opinion, approval expec
Slide 18: Launching a new chapter in aesthetics
Launching a new chapter in aesthetics New Product Candidate Jeuveau™ High-Impact, Disruptive Launch + Expected to be the first known 900kDa molecule in the * High-touch pre-launch activities escalating into 2019 U.S. since Botox launched * Connected experience drives frictionless commerce ¢ EU /Cana
Slide 19: Slide 19
Slide 20: Appendix: Reconciliations of non-GAAP to GAAP Financial Measures
Appendix Reconciliations of non-GAAP to GAAP Financial Measures Evolus has presented Non-GAAP Loss and Non-GAAP operating expenses, which are calculated as GAAP Net loss and GAAP total operating expenses, respectively, excluding: (i) the revaluation of contingent royalty obligation payable and (ii)
Slide 21: Thank You
evolus” THANK YOU